- Home
- QTTB vs PULM Comparison
QTTB vs PULM Comparison
Compare QTTB & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTTB
- PULM
- Stock Information
- Founded
- QTTB 2015
- PULM 2003
- Country
- QTTB United States
- PULM United States
- Employees
- QTTB N/A
- PULM N/A
- Industry
- QTTB Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- QTTB Health Care
- PULM Health Care
- Exchange
- QTTB Nasdaq
- PULM Nasdaq
- Market Cap
- QTTB 23.3M
- PULM 20.5M
- IPO Year
- QTTB N/A
- PULM N/A
- Fundamental
- Price
- QTTB $1.67
- PULM $4.87
- Analyst Decision
- QTTB Hold
- PULM
- Analyst Count
- QTTB 8
- PULM 0
- Target Price
- QTTB $24.00
- PULM N/A
- AVG Volume (30 Days)
- QTTB 104.5K
- PULM 11.0K
- Earning Date
- QTTB 08-06-2025
- PULM 08-06-2025
- Dividend Yield
- QTTB N/A
- PULM N/A
- EPS Growth
- QTTB N/A
- PULM N/A
- EPS
- QTTB N/A
- PULM N/A
- Revenue
- QTTB N/A
- PULM $369,000.00
- Revenue This Year
- QTTB N/A
- PULM N/A
- Revenue Next Year
- QTTB N/A
- PULM $134.88
- P/E Ratio
- QTTB N/A
- PULM N/A
- Revenue Growth
- QTTB N/A
- PULM N/A
- 52 Week Low
- QTTB $1.35
- PULM $1.78
- 52 Week High
- QTTB $53.79
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- QTTB 42.51
- PULM 44.33
- Support Level
- QTTB $1.62
- PULM $4.65
- Resistance Level
- QTTB $1.82
- PULM $5.00
- Average True Range (ATR)
- QTTB 0.16
- PULM 0.16
- MACD
- QTTB -0.02
- PULM 0.06
- Stochastic Oscillator
- QTTB 10.42
- PULM 76.92
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).